(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Online

Drug Development Phase 3 and Regulatory Review

Review phase 3 clinical study activities and the regulatory requirements and components of an application for marketing approval in the US and EU.

Register

Overview

In the Drug Development Phase 3 and Regulatory Review module, learners will review clinical study activities that occur during phase 3, and the regulatory requirements for and components of an application for marketing approval in the US and EU.

Estimated time to complete module: 1.5 hours

This eLearning module can be purchased individually or as part of the Drug Development and Lifecycle Management eLearning Program.

Featured topics

  • Objectives and key players
  • Phase 3 activities
  • Safety reporting requirements
  • Regulatory review
  • The Common Technical Document
  • Case study
  • Review

Who should attend?

This module is designed for individuals who are new to, or changing roles in, the pharmaceutical and biotechnology industries. The module will also benefit professionals who work in the areas of:

  • Clinical Research
  • Project Management
  • Administrative Support
  • Quality Assurance
  • Regulatory Affairs
  • Manufacturing
  • Medical writing
  • Business Support

Learning objectives

  • At the conclusion of this course, participants should be able to:

    • List the clinical study activities of phase 3
    • Identify safety reporting requirements
    • Determine the regulatory review process in the US and Europe
    • Record the components of the CTD

    Have an account?

    Register

    Be informed and stay engaged.

    Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.